Zypitamag (pitavastatin magnesium) / Medicure, Zydus Lifesciences - LARVOL DELTA

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: Jun 2026 ➔ Dec 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Hoffmann-La Roche | Trial completion date: Dec 2025 ➔ May 2026 | Trial primary completion date: Dec 2025 ➔ May 2026

Trial completion date • Trial primary completion date • Genetic Disorders • Obesity

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Hoffmann-La Roche | Not yet recruiting ➔ Recruiting

Enrollment open • Genetic Disorders • Obesity

A Study Investigating the Safety of RO7795081 and the Effect of RO7795081 on How the Body Processes Pitavastatin and Rosuvastatin in Otherwise Healthy Overweight or Obese Adult Participants (clinicaltrials.gov) - P1 | N=40 | Not yet recruiting | Sponsor: Hoffmann-La Roche

New P1 trial • Genetic Disorders • Obesity

MEDICURE REPORTS FINANCIAL RESULTS FOR QUARTER AND YEAR ENDED DECEMBER 31, 2024 (Medicure Press Release) - "Recorded total net revenue from the sale of AGGRASTAT of $8.1 million during the year ended December 31, 2024 compared to $9.7 million for the year ended December 31, 2023 and; Recorded total net revenue from the Marley Drug business of $10.8 million ($3.2 million from sales of ZYPITAMAG, and $7.6 million from other pharmacy revenue) during the year ended December 31, 2024 compared to $9.6 million ($2.6 million from sales of ZYPITAMAG and $7.0 million from other pharmacy revenue) for the year ended December 31, 2023 and; Recorded total net revenue from the sale of ZYPITAMAG of $6.2 million ($3.0 million through the traditional insured channels, and $3.2 million through Marley Drug) during the year ended December 31, 2024 compared to $5.0 million ($2.4 million through the traditional insured channels, and $2.6 million through Marley Drug) for the year ended December 31, 2023."

Sales • Cardiovascular • Dyslipidemia

Medicure Reiterates its Commitment to Providing Exceptional Access to its Branded Pitavastatin (Zypitamag) to People Living With HIV (Issuer Direct) - "Medicure...reaffirms its commitment to providing affordable and straightforward access to its branded pitavastatin, ZYPITAMAG®, to people living with HIV through two important channels: its pharmacy subsidiary Marley Drug® and through the AIDS Drug Assistance Program (ADAP) Crisis Task Force formulary. Access to branded medications can be challenging, however Medicure recognizes that access to pitavastatin is more important than ever in light of the recently published REPREIVE study (Randomized Trial to Prevent Vascular Events in HIV), which reported the benefits of pitavastatin for people living with HIV who are at increased risk of developing heart and vascular diseases. The effect of ZYPITAMAG on cardiovascular morbidity and mortality has not been determined."

Clinical • Dyslipidemia